Contents

Glossary

1. Preliminary matters

• 1.7 Procedural matters
  • 1.7.1 Operations/policies of the Committee
    • 1.7.1.1 Item deleted
    • 1.7.1.2 Guidelines for confidential information - Medicines
    • 1.7.1.3 Derivative usage in the SUSDP
• 1.8 NDPSC Working Parties
  • 1.8.1 Trans-Tasman Harmonisation Working Party
    • 1.8.1.1 Foreshadowed harmonisation proposals - hyaluronidase and methyl salicylate
    • 1.8.1.2 Deferred harmonisation proposals from the June 2006 NDPSC Meeting
      • 1.8.1.2.1 Aspirin combined with caffiene, paracetamol or salicylamide
      • 1.8.1.2.2 Iron compounds, selenium, vitamin A
      • 1.8.1.2.3 Laxatives (aloes for internal use, aloin, bisacodyl, colocynth, ipomoea, jalap resin, sennosides, sodium picosulphate)
      • 1.8.1.2.4 Medicines in Schedules 5, 6 or 7 which are in a New Zealand medicines classification - nicotine, picric acid, pyrethrins, sodium hydroxide, tar and xylenols
      • 1.8.1.2.5 Other deferred harmonisation proposals - ketoprofen, meptazinol, pyrithione zinc
      • 1.8.1.3.2 Cadmium compounds including cadmium sulphide
    • 1.8.1.4 Post-meeting comment on the October 2006 harmonisation decision - quaternary ammonium compounds, alendronic acid, cobalt, ethylhexanediol, hexoprenaline, nicotinic acid, potassium chloride, rifamycin, thyrotropin-releasing factor, vecuronium, viprynium (pyrvinium), vitamin D

Top of page

2. Proposed changes/additions to Parts 1, 2, 3 and 5 of the Standard for the Uniform Scheduling of Drugs and Poisons

• 2.1 SUSDP, Part 1
  • 2.1.1 Interpretation of aerosol concentration in the SUSDP
• 2.2 SUSDP, Part 2
• 2.3 SUSDP, Part 3
  • 2.3.1 Item deleted
  • 2.3.2 Storage statements for Schedule 2
• 2.4 SUSDP, Part 5
  • 2.4.1 Appendix A exemption for medical devices

Agricultural/veterinary, industrial and domestic chemicals

3. Matters arising from the minutes of the previous meeting

4. Other outstanding matters from previous meetings

• 4.1 Methyl Methacrylate and Ethyl Methacrylate
• 4.2 Basic Orange 31
• 4.3 Sulfentrazone
• 4.4 Clothianidin
• 4.5 GHRH Injectable Plasmid
• 4.6 2,4-Dichlorophenoxyacetic Acid
• 4.7 Dichlorprop-P

5. Proposed changes/additions to the Standard for the Uniform Scheduling of Drugs and Poisons

• 5.1 SUSDP, Part 4
  • 5.1.1 Hydrocarbons, liquid
• 5.2 SUSDP, Part 5
  • 5.2.1 Appendix J

Top of page

6. Matters referred by the Australian Pesticides and Veterinary Medicines Authority

• 6.1 Bifenthrin
• 6.2 Betacyfluthrin
• 6.3 Hydrocortisone Aceponate
• 6.4 Pyrasulfatole
• 6.5 Procymidone

7. Matters referred by the Office of chemical safety (OCS) or the National Industrial Chemicals Notification and Assessment Scheme (NICNAS)

• 7.1 5,6-dihydroxyindoline

8. Other matters for consideration

• 8.1 Dimethicodiethylbenzalmalonate (Polysilicone-15)
• 8.2 Labelling for composite pack hair preparations including those containing phenylenediamines and toluenediamine

Pharmaceuticals

10. Matters arising from the minutes of the previous meeting (Post-meeting submissions under 42ZCY)

• 10.1 Fluoride

11. Other outstanding matters from previous meetings

• 11.1 Sedating antihistamines - Brompheniramine, Chlorpheniramine, Dexchlorpheniramine, Diphenhydramine, Diphenylpyraline, Doxylamine, Pheniramine, Promethazine, Trimeprazine, Triprolidine
• 11.2 Pantoprazole
• 11.3 Orlistat
• 11.4 Topical corticosteroids – Alclometasone, Clobetasone, Mometasone
• 11.5 Paracetamol 665 mg tablets
• 11.6 Tranexamic acid
• 11.7 Sumatriptan

Top of page

12. Proposed changes/additions to the Standard for the Uniform Scheduling of Drugs and Poisons

• 12.1 SUSDP, Part 4
  • 12.1.1 Hydrocortisone 0.5% with cinchocaine
  • 12.1.2 Ranitidine
  • 12.1.3 Benzydamine
  • 12.1.4 Clotrimazole
  • 12.1.5 Chlorhexidine
• 12.2 SUSDP, Part 5
  • 12.2.1 Hydroquinone

13. Matters referred by Australian Drug Evaluation Committee (ADEC)

• 13.1 New substances (not seen before by NDPSC)
  • 13.1.1 Natalizumab
  • 13.1.2 Gadofosveset trisodium
  • 13.1.3 Ivabradine
  • 13.1.4 Sunitinib

14. Other matters for consideration

• 14.1 Child Resistant Packaging
• 14.2 Unscheduled analgesic & nicotine products - "Keep out of reach of children" label statement

15. Matters referred by the Medicines Evaluation Committee (MEC)

16. Matters referred by the Medicines Classification Committee (MCC) of New zealand

• 16.1 MCC new S4 medicines

17. Minutes of the Adverse Drug Reactions Advisory Committee (ADRAC)

• 17.1 Item deleted

18. Minutes of the Medical Device Evaluation Committee (MDEC)

19. Gazettal notices

20. Amendments to the SUSDP

• 20.1 Editorial changes and errata (Beclomethasone, Budesonide, Carbon Disulphide, 2,4-dichlorprop, Fluticasone, Hydrogen Sulphide, Ibuprofen, Prochlorperazine and Triamcinolone)